Transcriptomics paving the way for improved diagnostics and precision medicine of acute leukemia

Research output: Contribution to journalArticlepeer-review

Abstract

Transcriptional profiling of acute leukemia, specifically by RNA-sequencing or whole transcriptome sequencing (WTS), has provided fundamental insights into its underlying disease biology and allows unbiased detection of oncogenic gene fusions, as well as of gene expression signatures that can be used for improved disease classification. While used as a research tool for many years, RNA-sequencing is becoming increasingly used in clinical diagnostics. Here, we highlight key transcriptomic studies of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) that have improved our biological understanding of these heterogeneous malignant disorders and have paved the way for translation into clinical diagnostics. Recent single-cell transcriptomic studies of ALL and AML, which provide new insights into the cellular ecosystem of acute leukemia and point to future clinical utility, are also reviewed. Finally, we discuss current challenges that need to be overcome for a more wide-spread adoption of RNA-sequencing in clinical diagnostics and how this technology significantly can aid the identification of genetic alterations in current guidelines and of newly emerging disease entities, some of which are critical to identify because of the availability of targeted therapies, thereby paving the way for improved precision medicine of acute leukemia.

Original languageEnglish
Pages (from-to)40-49
JournalSeminars in Cancer Biology
Volume84
Early online date2021
DOIs
Publication statusPublished - 2022

Subject classification (UKÄ)

  • Cancer and Oncology

Keywords

  • Acute lymphoblastic leukemia
  • Acute myeloid leukemia
  • Classification
  • Diagnostics
  • Gene fusions
  • Precision medicine
  • RNA-sequencing
  • Whole transcriptome sequencing

Fingerprint

Dive into the research topics of 'Transcriptomics paving the way for improved diagnostics and precision medicine of acute leukemia'. Together they form a unique fingerprint.

Cite this